The fund's core objective is to generate significant capital appreciation over the long term. It allocates a minimum of 80% of its total portfolio to equity investments, primarily common stocks, of companies engaged in the health sciences and related fields. This broad health sciences sector includes enterprises involved in healthcare equipment and supplies, healthcare providers and services, biotechnology, and pharmaceuticals.
